SCHEMBL22408039

SCHEMBL22408039

Cc1cc2c(Cl)ccc(F)c2[nH]1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.36
CYP1A2 P05177 1/20 0.36
HPGD P15428 1/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 2/20 0.35
ADRA2A P08913 1/20 0.35
CLCN2 P51788 1/20 0.35
IDO1 P14902 2/20 0.35
TDO2 P48775 2/20 0.35
ALDH1A1 P00352 1/20 0.33
POLB P06746 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
HRH4 Q9H3N8 1/20 0.33
KEAP1 Q14145 1/20 0.33
NFE2L2 Q16236 1/20 0.33
PARP1 P09874 1/20 0.33
KIT P10721 3/20 0.32
KDM4E B2RXH2 1/20 0.32
PTGES O14684 1/20 0.31
MAP2 P11137 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22408352 0.86 ADRA2A (0.39) GAACYP1A2HPGDLMNAMAPT
SCHEMBL21886096 0.86 HRH4 (0.40) GAACYP1A2HPGDLMNAMAPT
SCHEMBL19014155 0.84 MAPT (0.39) GAACYP1A2HPGDLMNAMAPT
SCHEMBL22408523 0.80 KDM4E (0.41) GAACYP1A2HPGDLMNAMAPT
SCHEMBL24136220 0.80 IDO1 (0.36) GAACYP1A2MAPTADRA2ACLCN2
SCHEMBL30097033 0.77 IDO1 (0.35) GAAHPGDLMNAMAPTIDO1
SCHEMBL22407873 0.77 GRIN2D (0.33) GAACYP1A2MAPTALDH1A1POLB
SCHEMBL22408226 0.77 IDO1 (0.35) GAAHPGDLMNAMAPTIDO1
SCHEMBL25134417 0.77 EIF4A3 (0.33) GAACYP1A2HPGDLMNAMAPT
SCHEMBL28844721 0.75 IDO1 (0.65) LMNAIDO1TDO2RAPGEF4SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3928836-B1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2024-09-18 EP disclosed
US-12011444-B2 N-substituted indole derivatives as PGE2 receptor modulators IDORSIA PHARMACEUTICALS LTD (CH) 2024-06-18 US disclosed
EP-3377483-B9 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2022-08-03 EP disclosed
US-20220175775-A1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2022-06-09 US disclosed
US-11241431-B2 N-substituted indole derivatives as PGE2 receptor modulators IDORSIA PHARMACEUTICALS LTD (CH) 2022-02-08 US disclosed
EP-3928836-A1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS Idorsia Pharmaceuticals Ltd (CH) 2021-12-29 EP disclosed
CN-108349949-B N-substituted indole derivatives as PGE2 receptor modulators 爱杜西亚药品有限公司 2020-11-17 CN disclosed
US-20200289507-A1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2020-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200289507-A1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS PTGER1, PTGER4, PTGER2 GAA 4885/4885CYP1A2 104/4885HPGD 178/4885
US-20220175775-A1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS PTGER1, PTGER4, PTGER2 GAA 4885/4885CYP1A2 104/4885HPGD 178/4885
US-12011444-B2 N-substituted indole derivatives as PGE2 receptor modulators PTGER1, PTGER4, PTGER2 GAA 4885/4885CYP1A2 104/4885HPGD 178/4885
US-11241431-B2 N-substituted indole derivatives as PGE2 receptor modulators PTGER1, PTGER4, PTGER2 GAA 4885/4885CYP1A2 104/4885HPGD 178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.